EGFR and neoplasm: Nevertheless, resistance to third-generation EGFR TKIs can still develop through further mutations in EGFR and the activation of alternative pathways.[4] With the development of high-throughput NGS-based liquid biopsy technology, additional mechanisms, such as EGFR exon 20 C797S, EGFR L718Q, and EGFR exon 18 G724S mutations were observed.[4,5] NGS-based liquid biopsy testing overcomes spatial heterogeneity and can dynamically monitor tumor genomic evolution and guide decision-making for treatment strategies in a minimally invasive manner.[6]